PRISE (Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Established Onset Type 1 Diabetes Treated With Human Anti-Thymocyte Globulin [h-ATG]) Study

NCT07670650 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

108

Enrollment

OTHER

Sponsor class

Conditions

Type 1 Diabetes (T1D)

Interventions

DRUG: SAB-142
DRUG: Placebo

Sponsor

University of Florida

Collaborators

[object Object]
[object Object]